Search results
Results from the WOW.Com Content Network
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
Idoxuridine is an anti-herpesvirus antiviral drug. It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the iodine atom added to the uracil component blocks base pairing. It is used only topically due to cardiotoxicity. It was synthesized by William Prusoff in the late ...
Nirmatrelvir/ritonavir is under investigation, so its side effects have yet to be fully evaluated and may not be completely known. [ 19 ] Other side effects of nirmatrelvir/ritonavir may include hypersensitivity reactions , liver toxicity , and development of HIV drug resistance in people with uncontrolled or undiagnosed HIV infection .
Oseltamivir, sold under the brand name Tamiflu among others, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. [5] Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. [6]
The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. [11] [13] These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects and toxicity. [8]
Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is almost always used in combination with other antiretroviral drugs. Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (K i = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase ...
A string of other amyloid-targeting drugs have failed and many researchers now think combination treatments will be needed. Aduhelm, the similar drug, was marred by controversy over its effectiveness.
The main outcome measured in the trial was the percentage of people who were hospitalized or died due to any cause during 29 days of follow-up. [10] Of the 709 people who received molnupiravir, 6.8% were hospitalized or died within this period compared to 9.7% of the 699 people who received a placebo. [10]